DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
53	シェーグレン症候群	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01008982 (ClinicalTrials.gov)	August 2009	5/11/2009	Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome	A Phase 2, Proof of Concept, 52-Week Open Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Primary Sjögren's Syndrome.	Sjögren's Syndrome	Drug: LimphoStat-B	University of Udine	Azienda Ospedaliera S. Maria della Misericordia	Completed	18 Years	90 Years	Both	15	Phase 2	Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01008982
(ClinicalTrials.gov)

August 2009

5/11/2009

Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome

A Phase 2, Proof of Concept, 52-Week Open Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Primary Sjögren's Syndrome.

Sjögren's Syndrome

Drug: LimphoStat-B

University of Udine

Azienda Ospedaliera S. Maria della Misericordia

Completed

18 Years

90 Years

Both

Phase 2

Italy